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Abstract 
DNA replication is fundamental for cell proliferation in all organisms. Nonetheless, 
components of the replisome have been implicated in human disease and here we report 
PRIM1, encoding the catalytic subunit of DNA primase, as a novel disease gene. Using a 
variant-classification agnostic approach, biallelic mutations in PRIM1 were identified in five 
individuals. PRIM1 protein levels were markedly reduced in patient cells, accompanied by 
replication fork asymmetry, increased inter-origin distances, replication stress and 
prolonged S-phase duration. Consequently, cell proliferation was markedly impaired, 
explaining the patients’ extreme growth failure. Notably, phenotypic features distinct from 
those previously reported with DNA polymerase genes were evident, highlighting differing 
developmental requirements for this core replisome component that warrant future 
investigation. 
Introduction  
Microcephalic primordial dwarfism (MPD) disorders constitute several Mendelian 
syndromes characterized by intrauterine growth retardation, short stature, and microcephaly 
(Klingseisen and Jackson 2011). Previously, partial loss of function mutations have been 
identified in genes encoding fundamental components of the cell-cycle machinery, 
suggesting a model in which disrupted cell proliferation during development results in 
“hypocellular” forms of dwarfism (Klingseisen and Jackson 2011). 
Perturbation of components of the DNA replication machinery has emerged as a common 
cause of MPD, involving several stages of the replication process. In the G1-phase of the cell 
cycle the pre-replication complex acts to license replication origins, and subsequently the 
replication pre-initiation complex is formed, with the full replisome assembled at S-phase 
entry, to initiate DNA replication effected by three DNA polymerases, alpha, delta and 
epsilon (Pol α, δ and ε). Biallelic mutations in components of the pre-replication complex 
were first identified, with ORC1, ORC4, ORC6, CDT1, and CDC6, causing Meier-Gorlin 
Syndrome (MGS) (Bicknell et al. 2011b, 2011a; Guernsey et al. 2011), a disorder defined by a 
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triad of microtia, patella hypoplasia and growth restriction.  Heterozygous stabilizing 
mutations in GMNN and recessive variants in CDC45, MCM5 and DONSON  have 
subsequently been associated with MGS (Burrage et al. 2015; Vetro et al. 2017; Fenwick et al. 
2016; Reynolds et al. 2017).  Mutations in pre-initiation complex components MCM4, and 
GINS1 cause distinct microcephalic dwarfism syndromes with immunodeficiency and/or 
adrenal failure (Gineau et al. 2012; Cottineau et al. 2017). Finally, mutations  in genes 
encoding subunits of the replicative DNA polymerases POLA1, POLD1, POLD2, POLE and 
POLE2 have implicated components of the active replisome in primordial dwarfism, often 
with immune deficiency, and in the case of POLE, adrenal failure (Pachlopnik Schmid et al. 
2012; Thiffault et al. 2015; Frugoni et al. 2016; Logan et al. 2018; Van Esch et al. 2019; 
Conde et al. 2019).  
Each of these genes has been shown to be essential for cellular survival in large-scale 
functional screens (Table S1) (Chen et al. 2017) while constraint metrics from the gnomAD 
consortium suggest that loss of a single copy is unlikely to result in developmental disease 
(Table S2) (Karczewski et al. 2019). Recessive pathogenic variants are therefore most likely 
to lead to perturbation of function more severe than haploinsufficiency but falling short of 
biallelic loss of function. Consistent with this, previously published variants associated with 
recessive MPD have included hypomorphic missense or splice altering variants that result in 
at least one allele with residual function. The recent identification of an intronic splice 
altering mutation in POLE in 12 families exemplifies this, where each affected individual 
inherited different loss of function alleles in trans with the same intronic variant 
(c.1686+32C>G) causing a hypomorphic splicing defect. Hypomorphic alleles such as this 
may not be annotated as deleterious by variant classifiers, so we considered whether 
additional genes for MPD could be detected by using a variant-classification agnostic 
approach to identify as yet undiscovered cryptic mutations in essential genes. Here, we 
report the identification of PRIM1 as an MPD gene, and demonstrate that mutations reduce 
cellular PRIM1 protein levels, impairing DNA replication. 
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Results 
Identification of Biallelic Variants in PRIM1  
We analyzed whole genome (WGS) and whole exome (WES) sequence data from 220 
families with microcephalic dwarfism spectrum disorders (occipital-frontal circumference 
[OFC] ≤ -4 SD; height ≤ -2 SD),  to find variants enriched in this cohort relative to the 
general population and inherited in a pattern consistent with recessive inheritance 
(Materials & Methods, Supplemental Table S3). This identified three families sharing a 
homozygous intronic variant (c.638+36C>G, Fig. 1A,B) in PRIM1, which encodes the 
catalytic subunit of DNA primase.  
Supporting its pathogenicity, the intronic PRIM1 variant was significantly enriched in our 
microcephalic dwarfism cohort in comparison to the Genome Aggregation Database where 
just 2 heterozygotes out of 141,456 individuals were observed (gnomAD v2.1.1, p=3.61 x 10-15, 
all populations, combined WES and WGS data, Supplemental Table S4).  
Inbreeding coefficients in all three families were consistent with parental relatedness 
(Supplemental Table S5).  As well, P1-P4 had large overlapping regions of homozygosity 
between 10.4 Mbp and 32.7 Mbp in length on chromosome 12 containing the PRIM1 gene 
(Supplemental Fig. S1). These findings provided additional genetic support for PRIM1 being 
the causative gene as they were consistent with the expectation for consanguineous families 
with a rare recessive disease that a disease-causing variant is expected to lie within a region 
of homozygosity in each family (Lander and Botstein 1987). Within the shared region of 
homozygosity there was also a common 2 Mb haplotype surrounding the PRIM1 variant in 
all 4 affected individuals (Supplemental Fig. S1, Supplemental Table S7). This indicates that 
all 3 families share a distant common ancestor (Supplemental Fig S1, Supplemental Table 
S5), establishing the causal mutation to be within the haplotype and excluding the only other 
enriched variant in families 2 and 3, a missense change in OR6C4. 
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Analysis of the c.638+36C>G variant with SpliceAI (Jaganathan et al. 2019), NNSplice 
(Reese 1997) and MaxEntScan (Yeo and Burge 2004) predicted activation of a cryptic donor 
site, resulting in the inclusion of 31 nucleotides of intronic sequence following exon 6, 
expected to disrupt the open reading frame. This, alongside PRIM1 function in DNA 
replication, provided further support for disruption of PRIM1 causing MPD. 
To identify additional disease-causing PRIM1 alleles, we searched exome data from a subset 
of 149 trios and singletons from the Deciphering Developmental Disorders (DDD) project 
selected on the basis of morphometric criteria (OFC ≤ -3 SD and height ≤ -3 SD) and absence 
of previous diagnostic variants identified by DDD. This identified a single individual (P5) 
compound heterozygous for an essential splice donor variant (c.103+1G>T) and a missense 
variant (c.901T>C, p.Cys301Arg, hereafter referred to as C301R). These variants were 
respectively extremely rare or absent from public databases (Table 1). Additional analysis of 
exome data from P5 did not reveal any other likely diagnostic variants as an alternative 
explanation. The c.103+1G>T variant results in loss of the donor site of intron 1 while the 
c.901T>C variant alters a cysteine residue, conserved in vertebrates, to a physiochemically 
dissimilar arginine. This substitution was predicted damaging by in silico tools including 
PolyPhen2, SIFT, MutationTaster and CADD (CADDv1.6 Phred score=28.4). 
PRIM1 subjects share a distinct clinical phenotype 
A similar clinical phenotype was evident in all five individuals. All had extreme growth 
failure, with in utero growth retardation (birth weight -3.4 ± 0.6 SD) and severe postnatal 
growth restriction (height -8.8 ± 2.0 SD) (Fig. 1C, Supplemental Table S8). While relatively 
macrocephalic, in absolute terms there was extreme microcephaly (OFC -6.0 ± 1.5 SD). On 
neuroimaging this was reflected by a ‘microcephaly with simplified gyri’ appearance (Fig. 
1D). A common facial appearance was apparent, with prominent forehead and triangular 
face, with blepharophimosis ± microphthalmia, micrognathia and small low-set ears (Fig. 
1E). Absence of subcutaneous fat, and distally tapered fingers were noted in all affected 
individuals on clinical examination. Hypothyroidism was frequent alongside significant 
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haematological/immune dysfunction. All had hypo/agammaglobulinemia (Table 2). In four 
of five cases there was persistent lymphopenia accompanied by intermittent 
anemia/thromobocytopenia. Documented episodes of sepsis occurred in several patients. In 
addition, episodes of fever without an identified infective source were recorded. All 
individuals had chronic respiratory symptoms, and four died in early childhood from either 
respiratory or GI infections. Hepatic dysfunction was noted clinically, and at postmortem, 
hepatic fibrosis, cirrhosis or macronodular regeneration was evident in three of these 
individuals, suggesting preceding chronic liver inflammation. 
The distinct clinical phenotype in these individuals was consistent with a shared genetic 
etiology, taken together with our genetic data, led us to conclude that biallelic mutations in 
the PRIM1 gene cause MPD. Next, we sought to test the functional impact of the variants 
identified in PRIM1. 
The c.638+36C>G variant activates a cryptic splice site reducing cellular PRIM1 
protein 
To confirm that the c.638+36C>G variant resulted in mis-splicing, RT-PCR was performed 
on RNA extracted from a lymphoblastoid cell line (LCL) established from individual P2 and 
from primary fibroblasts cultured from individual P3. This demonstrated the presence of an 
additional PCR product in P2 and P3 corresponding in size to the predicted mis-spliced 
transcript (Fig. 2A). Sanger sequencing of these PCR products confirmed in silico splice 
predictions, with the presence of an additional 31 nucleotides of intronic sequence (Fig. 
2B,C) leading to substitution of a lysine to serine at codon 214 and a frameshift with 
premature termination 21 amino-acids later (HGVS nomenclature: p.Lys214Serfs*21, 
referred to hereafter as K214fs). This would be anticipated to lead to nonsense-mediated 
decay (NMD) of this transcript, with any remaining translated truncated protein not 
containing key catalytic residues and therefore enzymatically inactive (Fig. 1B). Reduced 
cellular levels of full-length protein were therefore expected, and consistent with this, 
marked reduction in full-length PRIM1 protein levels was evident on immunoblotting of cell 
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extracts from P2 and P3 in comparison to control cell lines (Fig. 2D; 14% of wild-type levels 
in patient LCL and 9% in fibroblasts). (A band at ~25 kDa, that might correspond to a non-
functional truncated PRIM1 protein (27 kDa), was seen inconsistently in blots from P2 LCL 
extracts but not in P3 fibroblasts, Supplemental Fig. S2). 
C301R and c.103+1G>T variants also reduce PRIM1 protein levels 
P5 was compound heterozygous for c.103+1G>T and C301R variants. However, a patient cell 
line was not available, therefore the consequences of these variants were assessed by 
different methodologies. Our initial expectation was that essential splice site mutation would 
be a null allele and the missense variant, partial loss of function.  
C301 is a residue in a buried hydrophobic region of the protein (Fig. 3A), and its substitution 
with a bulky, positively charged arginine residue (C301R) was predicted to be highly 
destabilizing by FoldX (Schymkowitz et al. 2005) (Supplemental Fig. S3). We therefore 
assessed the effect of this substitution on PRIM1 protein levels, developing a FACS-based 
assay to measure the level of PRIM1-GFP containing this insertion relative to a co-translated 
RFP control (Fig 3B). This approach corrects for cell to cell variation in transfection 
efficiency and ensures that assessment of protein expression is not confounded by 
transcriptional differences or mRNA stability. This assay confirmed substantially reduced 
PRIM1 protein levels for the C301R substitution (25 ± 0.3%, Fig. 3C,D). 
We also modelled this mutation in budding yeast, where substitution of the equivalent 
residue in S. cerevisiae Pri1p to arginine (L309R) also led to a reduction in protein level 
(Supplemental Fig. S4), whereas the wild-type human cysteine residue (L309C) had no effect 
on either the level of Pri1 protein (Supplemental Fig. S4) or growth (Supplemental Fig. S5). 
Similar degradation dynamics of wild-type and L309R Pri1p in cycloheximide chase 
experiments (Supplemental Fig. S4) suggest that reduced protein levels are most likely the 
consequence of incorrect folding of the C301R/L309R protein rather than an increase in 
turnover. Notably C301 is in close proximity to the key catalytic residue R304 (Kirk and 
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Kuchta 1999), suggesting that it might not solely act to reduce protein levels. Consistent with 
this, the L309R mutation was lethal in yeast (Supplemental Fig. S5), raising the possibility 
that C301R in human PRIM1 is also a null allele, as disturbance of this catalytic site could 
potentially lead to loss of function in any mutant protein that persists in the cell. 
The C301R substitution appeared to be of greater functional severity than expected, so we 
examined the c.103+1G>T variant in more detail, considering whether it might instead be 
hypomorphic in effect. Consistent with this possibility, a minigene assay established that the 
c.103+1G>T variant could lead to the use of a nearby cryptic splice site (Fig. 3E, 
Supplemental Fig. S6) resulting in a 3 amino acid in-frame insertion in the PRIM1 transcript 
(‘V35insDGV’, Fig. 3F,G). The FACS-based stability assay established that the V35insDGV 
insertion also lowers PRIM1 protein levels (52 ± 0.5% of wild-type levels, Fig. 3C,D), but less 
severely than C301R, consistent with this being a partial loss of function mutation.  
In conclusion, these experiments confirmed that both variants have functional impact on the 
PRIM1 protein, that in combination would still leave residual PRIM1 activity.  
Fork stability and origin firing is impaired in PRIM1 primary fibroblasts 
Human PRIM1 encodes the 49 kDa catalytic subunit of the DNA primase heterodimer, which 
forms a heterotetrameric complex with the two DNA polymerase α subunits (Czechowska 
and Błasiak 2005). PRIM1 is responsible for the synthesis of short RNA primers required for 
the initiation of DNA replication and Okazaki fragment synthesis, before handover of these 
primers to Pol α for DNA synthesis (Rowen and Kornberg 1978; Frick and Richardson 2001). 
As such, depletion of PRIM1 would be expected to impact the efficiency of DNA replication. 
Doubling times of P3 primary fibroblasts were significantly increased compared to controls 
(Fig. 4A, P3 = 49 ± 3.6 hours, C1 = 23 ± 2.9 hours, C2 = 27 ± 2.3 hours, P < 0.001) (Fig. 4A), 
and S-phase length, measured by sequential CldU/IdU pulse labelling (Martynoga et al. 
2005), was substantially increased (P3 = 16.6 ± 0.12 hours, C1 = 6.1 ± 0.4 hours, C2 = 7.2 ± 1 
hours) (Fig. 4B,C). Complementation by transient transfection of wild-type, but not C301R 
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mutant PRIM1 confirmed that the lengthened S-phase was specifically due to PRIM1 
deficiency in patient cells (Fig. 4D,E). Impaired efficiency of DNA replication was also 
observed in BrdU-DNA content flow cytometry which demonstrated reduced BrdU 
incorporation in P3 primary fibroblasts during S-phase compared with control fibroblast 
lines (P < 0.001, Fig. 4F,G). In addition, γH2AX levels, a marker of DNA damage, were 
significantly increased in patient fibroblasts during S-phase (Fig. 4H), as were levels of 
chromatin bound RPA (Supplemental Fig. S7), consistent with the presence of endogenous 
replication stress. However, whether S-phase checkpoint activation occurs remains to be 
determined. 
FACS analysis of the cell cycle also demonstrated an increased proportion of G1-phase cells 
(Fig. 4F, Supplemental Fig. S8), without significant differences in the fraction of cleaved 
caspase-3 or p21-positive patient cells  (Supplemental Fig. S9). We therefore concluded that 
the hypoproliferative phenotype was most likely the consequence of delayed cell-cycle 
progression rather than increased apoptosis or cell-cycle exit.  
We used DNA-fiber combing to further characterize replication defects in PRIM1 deficient 
patient cells. Primary fibroblasts from P3 demonstrated similar replication defects to 
fibroblasts from an individual with POLE-IMAGe syndrome caused by Pol ε deficiency (P1 
from Logan et al. 2018). Fork speed was not affected in either PRIM1 or POLE cell lines (Fig. 
5B) but both cell lines displayed a similar, high degree of perturbed fork-progression 
compared to controls (Fig. 5C), indicative of elevated fork stalling and restart events, as 
might be expected for an enzyme continually required for priming of Okazaki fragments 
during lagging strand synthesis. Increased inter-origin distances were also observed [median 
IOD 152 Kbp vs. 113 Kbp, P < 0.001], (Fig 5D), suggesting reduced DNA replication initiation 
at origins. These alterations in replication dynamics were similarly observed in P2 LCLs 
(Supplemental Fig. S10).   
 Taken together, these findings were consistent with impaired replication fork formation and 
increased replication fork stalling in PRIM1 deficient cells. 
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Discussion 
We report here the identification of five individuals with biallelic deleterious variants in 
PRIM1, using a variant-classification independent approach. PRIM1 is essential to cellular 
survival (Chen et al. 2017) and, like other replisome components, knockout in mice is lethal 
during embryogenesis (Blake et al. 2011). Mutations in essential genes which result in 
developmental disorders are necessarily hypomorphic alleles. Identification of such variants 
is challenging, particularly as they may often be in non-coding regions (Tarnauskaitė et al. 
2019; Cottineau et al. 2017; Logan et al. 2018). Consequently, they may not appear on 
variant lists filtered by functional consequence. Therefore, the agnostic approach used in this 
study may have utility for the identification of further genes for other Mendelian diseases. 
PRIM1 deficiency results in similar growth restriction to other replication-associated 
disorders such as those associated with Pol α and Pol ε deficiency (Supplemental Fig. S11, 
Supplemental Fig. S12). Microtia and lymphopenia are also reminiscent of other replisome 
disorders (Conde et al. 2019; Logan et al. 2018).  Likewise, reduced subcutaneous fat in 
PRIM1 deficient individuals parallels the lipodystrophy found in POLD1 cases (who had 
normal growth) due to heterozygous single-codon deletion of the catalytic site of Pol δ 
(Weedon et al. 2013).  However, there are distinctive clinical features for individuals with 
PRIM1 deficiency, particularly early childhood mortality occurring in four out of five cases. 
While this might be accounted for by the significant B cell lymphopenia and accompanying 
hypo/agammaglobinemia, other disease processes may have also contributed. Chronic lung 
disease, recurrent diarrhea and liver dysfunction could also reflect a persisting inflammatory 
state. Notably a specific intronic variant in POLA1 causing an X-linked reticulate pigmentary 
disorder, is also associated with recurrent pneumonias and chronic diarrhea, with 
underlying immunodeficiency alongside autoinflammation (Starokadomskyy et al. 2016). 
However, the POLA1 associated reticulate pigmentary skin phenotype is not reported in any 
of the individuals with PRIM1 variants identified herein. Most individuals with MPD caused 
by POLA1 variants have growth retardation and microcephaly without such features (Van 
 
 
 
Parry et al. Page 11 
Esch et al. 2019), and facially PRIM1 deficiency appears distinct from these and individuals 
with POLE-associated IMAGe syndrome (Logan et al. 2018).  Likewise, blepharophimosis, 
microphthalmia, hypothyroidism, episodic thrombocytopenia and anemia do not appear to 
be features reported in other replisome disorders. 
In conclusion, we describe a distinct form of microcephalic dwarfism associated with PRIM1 
mutations. Similar to POLE/A1 DNA polymerase disorders, replication fork defects are seen 
in PRIM1 deficient cells. This likely reflects an inability of these cells to establish sufficient 
replication origins and sustain lagging strand synthesis at a sufficient rate to meet the 
demand for rapid replication. The ensuing delay to the cell cycle and reduced cellular 
proliferation provides a likely mechanism for the resulting “hypocellular” microcephalic 
dwarfism. Given the necessity of several polymerases to act in concert in every replicating 
cell, the different phenotypic manifestations of Pol α, Pol δ, Pol ε and DNA primase related 
disorders are surprising and require future investigation.  
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Materials and Methods 
Research subjects 
Genomic DNA was extracted from blood samples by standard methods or from saliva 
samples using Oragene collection kits according to the manufacturer’s instructions.  
Informed consent was obtained from all participating families. This study was approved by 
the Scottish Multicentre Research Ethics Committee (05/MRE00/74). Parents provided 
written consent for the publication of photographs of the affected individuals. 
The DDD study has UK Research Ethics Committee approval (10/H0305/83, granted by the 
Cambridge South REC, and GEN/284/12 granted by the Republic of Ireland REC). 
Whole-Genome Sequencing and Variant Calling 
Whole Genome Sequencing in P1, P2 and P4 was performed by Edinburgh Genomics 
(Clinical Division) as part of the Scottish Genomes Project (SGP) to 30X coverage using 
TruSeq Nano library preparation kits and a HiSeq X sequencing platform (Illumina).  
FASTQs generated by Edinburgh Genomics were aligned to the human genome (hg38, 
including alt, decoy and HLA sequences) using bwa mem(Li 2013) (0.7.13). Post-processing 
was performed with samblaster (Faust and Hall 2014) (0.1.22) to mark duplicate reads, and 
the Genome Analysis ToolKit(McKenna et al. 2010) (GATK, v3.4-0-g7e26428) for indel 
realignment and base recalibration. Genotype likelihoods for each sample were calculated 
using the GATK HaplotypeCaller and resulting GVCF files were called jointly using GATK’s 
GenotypeGVCFs function. Variant quality score recalibration (VQSR) was performed as per 
GATK best-practices(Van der Auwera et al. 2002) and a truth sensitivity threshold of 99.9% 
applied. Functional annotations were added using Ensembl’s Variant Effect Predictor 
(McLaren et al. 2016) (v90). 
Variant Filtering and Identification of a Variant Activating a Cryptic Splice 
Donor in PRIM1 
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Cohort WGS variant data were filtered to only include variants with an allele frequency < 0.5 
% in all gnomAD populations at biallelic sites outside of repeat masked or low-complexity 
regions using VASE (v0.1, https://github.com/david-a-parry/vase). Remaining variants were 
analyzed against gnomAD v2.1 data converted to hg38 coordinates. 
Where variants were present in gnomAD WES and WGS VCFs, allele counts per population 
were extracted from VCFs. For variants absent from either or both gnomAD WES or WGS 
VCFs, homozygous reference allele counts were derived for the respective samples using 
sequencing depth data, where the fraction of individuals with sequencing depth ≥ 5 were 
counted as homozygous reference. Variants were annotated with P-values from one-tailed 
Fisher’s exact tests comparing the alternate/reference allele counts in non-related affected 
individuals in the MPD cohort versus individual population groupings in gnomAD. 
Annotated variants were assessed for segregation consistent with recessive inheritance. At 
least one allele was required to have P-values below 5 x 10-5 for each of the African/African-
American, Latino/Admixed American, East Asian, Finnish, Non-Finnish European and 
South Asian gnomAD subpopulations. The second allele for a gene was required to either 
match these same criteria or to be a predicted loss-of-function variant. Analysis was 
restricted to canonical transcripts and biallelic combinations of alleles observed in non-
affected family members were excluded. Where available, phase information from parental 
genotypes and/or physical phasing was used to exclude biallelic combinations in cis. 
This enrichment strategy could be confounded by differing variant calling sensitivity in 
gnomAD compared to the MPD cohort and by population stratification. In order to mitigate 
these effects we required enriched alleles to be below the given P-value threshold in each of 
the population groups listed above and then ranked genes based on incidental occurrences of 
variants within the MPD cohort, gene essentiality and the maximum (least significant) 
observed P-value. Incidental occurrences were defined as the number of families where an 
individual was a carrier for a variant yet no qualifying second allele was observed in the 
affected individual(s). Additionally, more than 2 qualifying alleles in the same family were 
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also defined as incidental occurrences to address the presence of ‘noisy’ genes. Gene 
essentiality was defined as the fraction of studies in OGEE (Chen et al. 2017) in which a gene 
was found to be cell-essential. A ranking score for variants was calculated as follows: 
𝑠𝑠 = (1 + 𝑜𝑜𝑜𝑜)(1 + 𝑓𝑓𝑜𝑜)(1.1 −  𝑒𝑒𝑠𝑠𝑠𝑠) 
Where “oi” indicates the number of incidental occurrences in other families, “fi” indicates the 
number of incidental occurrences within the same family and “ess” represents the fraction of 
studies in which the gene is considered cell essential. A lower score was considered “better” 
such that variants were penalised for incidental occurrences and lack of evidence for gene 
essentiality. 
These methods are implemented in a python package (ReVERSe), available at 
https://git.ecdf.ed.ac.uk/dparry/reverse. 
Segregation Filtering of DDD CAPS14 Cohort 
VASE (v0.1, https://github.com/david-a-parry/vase) was used to perform variant filtering 
and segregation analysis. Variants overlapping PRIM1 were filtered to remove those with a 
frequency greater than 0.5% in gnomAD or dbSNP151. Additionally, those variants not 
predicted to either be protein altering variants, within a splice region or with a SpliceAI 
(Jaganathan et al. 2019) delta score ≥0.5 were also excluded. Genotype calls were filtered if 
samples had fewer than 5 reads covering the site or the fraction of variant reads to total reads 
(VAF) were less than 0.25. Remaining variants were assessed for familial segregation 
consistent with recessive inheritance. 
Following identification of PRIM1 compound heterozygous variants in F5, variant data for 
this family was re-analysed to test exome-wide for any other possible causative variants. 
Data for this family was analysed exome-wide for recessive variants as above and also 
analysed for de novo variants, requiring a VAF ≥ 0.25 in the proband and VAFs < 0.05 in 
both parental genotypes and total site depths of ≥ 8 in parents and proband. 
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Plasmid construction 
All oligonucleotides and plasmids used in this study are listed in Supplemental Tables S9 and 
S10 respectively. Plasmids pMAR780 and 781 were generated by cloning annealed 
oligonucleotides into BclI/SwaI digested pML104 and pML107 plasmids, 
respectively(Laughery et al. 2015). To construct pMAR782, the PRI1 (YIR008C) coding 
sequence, without stop codon and with a silent PAM site mutation (c.1945G>C), was 
amplified by PCR using MRY201 genomic DNA as template and cloned into XbaI/BamHI 
digested pGFP-C-FUS(Niedenthal et al. 1996). pMAR782 allows expression of C-terminally 
GFP-tagged Pri1 protein in medium lacking methionine. To construct pMAR790, a 1.35 kb 
fragment of human genomic DNA (chr12:56750975-56752323, hg38) covering PRIM1 exon1 
and exon 2 was PCR amplified and cloned into BspEI/XbaI sites of RHCglo (a gift from 
Thomas Cooper; Addgene plasmid # 80169)  (Singh and Cooper 2006), fusing PRIM1 exon 1 
with exon 1 of the minigene construct. The donor (c.103+1G>T) splice site mutation was 
introduced in intron 1 using site directed mutagenesis (NEB Q5 Site-Directed Mutagenesis 
Kit), generating pMAR793. Human C-terminally EGFP-tagged PRIM1 was synthesized by 
IDT flanked by NheI and BspEI sites and provided in pUCIDT-AMP GoldenGate 
(pMAR796). The NheI/BspEI fragment was then transferred into pmGFP-P2A-K0-P2A-RFP 
(a gift from Ramanujan Hegde; Addgene plasmid # 105686) (Juszkiewicz and Hegde 2017), 
replacing mGFP and creating pMAR797. To introduce C301R and VDGins mutations, Q5 
SDM was performed on pMAR796, creating pMAR798 and 802 respectively, and the 
sequence-verified PRIM1-EGFP NheI/BspEI fragments cloned into pmGFP-P2A-K0-P2A-
RFP to make pMAR799 and 803. All plasmids were confirmed by restriction digest analysis 
and Sanger sequencing. 
Cells and Cell culture 
Primary dermal fibroblasts were established from skin punch biopsies and maintained in 
AmnioMAX medium (Thermo Fisher Scientific, Cat. No. 17001074) in 5% CO2 and 3% O2. 
Patient Lymphoblastoid cell lines (LCLs) were generated in house from peripheral blood 
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samples by EBV transformation using standard methods. LCLs were maintained in RPMI 
1640 supplemented with 15% FBS, L-glutamine and penicillin/streptomycin antibiotics. 
HeLa (ATCC) cells were maintained in DMEM supplemented with 10% FBS and 5% 
penicillin/streptomycin in 5% CO2, under normoxic conditions. Genotypes of patient cells 
lines were validated by Sanger sequencing. 
RT-PCR  
Total RNA was extracted from cell lines using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s instructions. Following DNase I (Qiagen) treatment cDNA was generated 
using SuperScript III Reverse Transcriptase (Thermo Fisher Scientific). RT-PCR was 
performed on cDNA using primers in exon 4 and 8 (Supplemental Table S9). 
Minigene splicing assay 
RPE1 cells were seeded (4 x 105 cells/well) in a 6-well plate. After 24 h, cells were transfected 
with 800 ng of pMAR790 or pMAR791 plasmid in Opti-MEM Reduced Serum Medium with 
Lipofectamine 2000 according to the manufacturer’s instructions. Cells were harvested after 
24 h, RNA extracted using the RNeasy Mini Kit (Qiagen), and cDNA generated using 
SuperScript™ III Reverse Transcriptase (Invitrogen). PCR amplification was then performed 
with RSV5U and RTRHC primers, and wild-type and mutant cDNA amplicons resolved by 
agarose gel electrophoresis to visualize splicing differences. PCR products were cloned into 
pGEM-T Easy (Promega), and Sanger sequencing performed on 20 clones.  
Immunoblotting 
Whole cell extracts were prepared by lysis using 50 mM Tris-HCl (pH 8), 280 mM NaCl, 
0.5% NP40, 0.2 mM EGTA, 1 mM DTT and 10% glycerol, supplemented with Roche 
Complete Protease Inhibitor Cocktail. Protein samples were resolved on 4-12% NuPAGE Bis-
Tris gels (Thermo Fisher Scientific) and transferred to nitrocellulose or PVDF membranes. 
Subsequent immunoblotting was performed using the following antibodies: anti-p48 
Primase (8G10; Cell Signalling, 4725, 1:1,000), anti-Vinculin (hVIN-1; Sigma-Aldrich, 
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V9264, 1:2,000), anti-α-Tubulin (B-5-1-2; Sigma-Aldrich, T6074, 1:10,000), anti-GFP 
(Living Colors JL-8; Clontech, 1:4,000), anti-FLAG (M2; Sigma-Aldrich, F1804, 1:2,000) or 
anti-Actin (Sigma-Aldrich A2066, 1:4,000). 
Finally, detection was performed using Amersham ECL Prime Western Blotting Detection 
Reagent on the ImageQuantLAS4000 (GE Healthcare Life Sciences), or the Odyssey CLx 
Imaging System (LI-COR Biosciences). Quantifications were performed using ImageQuant 
TL 7.0 and Image Studio Lite 5.2, respectively. 
FACS-based Dual Reporter Stability Assay 
C-terminally EGFP-tagged PRIM1 (wild-type or mutants) was cloned into a mammalian 
expression vector as described under Plasmid Construction. Expression from the CMV 
promoter of the resulting constructs (pMAR797 and derivatives) produces mRNA encoding 
PRIM1-EGFP-P2A-FLAG-SR-P2A-RFP, which when translated due to intervening P2A “self-
cleaving” peptide sequences produces 3 individual polypeptides in equimolar amounts: 
PRIM1-EGFP, FLAG-SR and RFP.  This allows comparison of the relative level of PRIM1-
EGFP (wild-type and mutants) and RFP in individual cells. 
RPE1 cells were seeded (4 x 105 cells/well) in a 6-well plate. and a day later transfected with 
2 µg of the reporter plasmid in Opti-MEM Reduced Serum Medium with Lipofectamine 
2000 as per manufacturer’s instructions. At 24 h post-transfection live cells were assayed for 
the presence of GFP and RFP using a BD Biosciences LSR Fortessa flow cytometer and data 
analyzed using FlowJo software (v7.6.1, Tree Star).  
BrdU-DNA content Flow cytometry 
Primary Fibroblasts were seeded into AmnioMAX medium (Life Technologies) to achieve 
~60% confluency after 24 h. Cells were then incubation with 10 μM BrdU for 30 min, 
washed, harvested and fixed with 70% EtOH at -20°C for 16 h. Fixed cells were then digested 
with 1 mg/ml pepsin, denatured in 2 M HCl for 15 min, and washed with PBS. After blocking 
in 0.5% BSA, 0.5% Tween-20, BrdU labelling was detected using anti- BrdU antibody 
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(Abcam, ab6326, 1:75) and anti-Rat Alexa-Fluor 488 secondary antibody (Thermo Fisher 
Scientific, A11006). DNA content was determined by co-staining with 50 μg/ml propidium 
iodide. Cells were assayed on a BD Biosciences LSR Fortessa flow cytometer and data 
analysed using FlowJo software (v7.6.1, Tree Star). 
Cell Proliferation Doubling Times 
Primary fibroblasts (1.5 x 105 cells) were seeded on day 0 into a T25 flask. Cell counts were 
performed every 3 days using a MOXI Z Mini automated cell counter (MXZ001). After 
counting, 1.5 x 105 cells were reseeded into a new T25. Doubling times were calculated during 
log-phase growth (day 3 to day 12) using the formula: 𝑡𝑡/ log2(
𝑒𝑒
𝑏𝑏
) where t = time in hours, e = 
final population size and b = population size at the start of log-phase growth. 
S-phase time measurements and PRIM1 complementation (CldU/IdU Pulse 
Labelling) 
S-phase time (Ts) measurements were performed using sequential pulses of CldU and IdU to 
determine the fraction of cells that leave S-phase in a specified time window, according to 
the formula Ts= Ti*Scells/Lcells, where Ti represents the time (hours) between pulses, Scells are 
the number of cells that are in S-phase at the first pulse (all CldU positive), and Lcells are the 
number of cells that have left S-phase at the time of the second pulse (CldU positive and IdU 
negative cells)..  
Primary fibroblasts, cultured on coverslips, were pulsed with 25 µM CldU for 1.5 hfollowed 
by a 30 min 125 µM IdU pulse. Cells were then fixed in 4% PFA. 
For complementation experiments, P3 fibroblasts were electroporated with dual expression 
vectors (pMAR797 and derivatives: empty vector or containing GFP-PRIM1 and GFP-
PRIM1-C301R) using the Invitrogen Neon Kit (Cat. No. MPK10096) according to 
manufacturer instructions (2.5 µg plasmid DNA for 1x106 cells, 20 ms pulse width). 24 h 
after electroporation, cells were pulsed with CldU and IdU (as above), trypsinised and sorted 
on a BD FACSAria to select GFP-positive, successfully transfected cells. Cells were collected 
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in AmnioMAX C-100, seeded on coverslips in 24-well plates for 1.5 h and subsequently fixed 
in 4% PFA. Immunofluorescence for CldU and IdU as outlined below, was performed using 
Rat anti-BrdU (Abcam, Cat. No. ab6326) and mouse anti-BrdU (BD, Cat. No. 347580). 
Immunofluorescence 
Fibroblasts were grown on coverslips for 24 h, fixed with 4% PFA, washed and blocked for 1 
h in 10% goat serum/PBS/0.1% Triton. Independent coverslips were incubated with p21 
(1:200, Calbiochem Cat. No. OP64), cleaved caspase 3 (1:1000, Cell Signaling, Cat. No. 
9661), γH2AX (1:1000, Millipore, Cat. N. 05-636) or RPA2 (1:200, Calbiochem, Cat. No. 
NA19L antibodies. After overnight incubation in primary antibodies, signals were detected 
using fluorescently conjugated antibodies and co-stained with DAPI. For all antibodies 
excepting cleaved caspase 3 and p21, cells were pre-extracted for 5 min on ice with ice-cold 
buffer (25 mM HEPES, pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose 
and 0.5% Triton X-100) before fixation to remove soluble proteins and detection of 
chromatin-bound fractions. For γ-H2AX staining, cells were pulsed with 20 µM EdU (Sigma, 
Cat No. 900584) for 1 h before fixation. EdU was detected subsequent to 
immunofluorescence using the click reaction and Azide-Alexa Fluor-488 (ThermoFisher 
A10266). 
DNA Combing 
Primary fibroblast cells exponentially growing in AmnioMAX C-100 (Thermo Fisher 
Scientific, Cat. No. 17001074) medium under hypoxic conditions were pulsed with 25 mM 
CldU (Sigma, Cat. No. C6891) for 20 min, washed with pre-warmed PBS and then pulsed 
with 125 mM IdU (Sigma, Cat. No. I7125) for 20 min. After trypsinization, 5x105 cells were 
used to cast 3-4 agarose (Biorad, Cat. No. 1613111) plugs per condition and processed for 
DNA combing according to a previously described protocol (Gallo et al. 2016), omitting the 
SCE buffer plug digestion steps. IdU and CldU were detected using mouse anti-BrdU (BD, 
Cat. No. 347580)  and rat anti-BrdU (Abcam, Cat. No. ab6326), respectively. DNA was 
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detected using anti-ssDNA antibody (Millipore, MAB 3034). Images were acquired on a 
widefield microscope (Zeiss Axiophot) with a 63X or 40X lens. The 2.33 Kbp/µm elongation 
rate (µm to Kbp conversion) was obtained from bacteriophage lambda DNA combing and 
measurement, as previously described(Gallo et al. 2016). Measurements and analysis were 
performed using ImageJ. DNA fork speed was obtained dividing the length of the IdU tracks 
adjacent CldU tracks (ongoing forks) by the IdU incubation time (20 min) and expressed in 
Kbp/min. Fork asymmetry is presented as left IdU vs. right IdU ratios.  Inter-origin 
distances (IODs) correspond to the space (in Kbp) between the centre points of adjacent bi-
directional replication origins. 
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Family 
  
Individual 
Allele 1 Allele 2   
Country 
of origin 
HGVSc HGVSp AF HGVSc HGVSp AF 
1 P1 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5  Hungary 
2 P2 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5  Hungary 
3 P3 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5  Hungary 
3 P4 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5 c.638+36C>G p.Lys214Serfs*21 1.49 x 10-5  Hungary 
4 P5 c.103+1G>T p.Val35_Ile36insAspGlyVal 2.03 x 10-5 c.901T>C p.Cys301Arg -  UK 
Table 1: PRIM1 Variants identified in individuals with MPD. Variants reported in this study are described using HGVS nomenclature 
(https://varnomen.hgvs.org/) for the reference coding DNA (HGVSc, NCBI Reference Sequence NM_000946.3) and protein (HGVSp, NCBI 
Reference Sequence NP_000937.1) sequences. The variant allele frequency (AF) for non-Finnish European populations in gnomAD is given for 
each variant. DNA variants are expressed relative to the coding (“c.”) sequence, and all protein changes are preceded by “p”. 
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Individual P1 P2 P3 P4 P5 
Family F1 F2 F3 F3 F4 
Gender Female Female Male Male Male 
Age Died at 7 mo 7 yrs Died at 2 yrs Died at 19 mo Died age 2 yrs 
Consanguinity y n/ab n n n 
IUGR, 
microcephaly & 
short staturec 
y y y y y 
Recurrent 
infections 
Klebsiella 
pneumoniaeg; 
Coag. neg. Staphg. 
Died of RSV + 
parainfluenza  
Ventriculitis (post-
shunt); Rotavirus, 
Clostridium 
difficile; Proteus 
mirabilisg. 
Respiratory + GI. 
Recurrent fevers. 
Died of Adenovirus 
infection. 
Respiratory + GI. 
Rotavirus enteritis. 
Enteropathogenic 
E.coli. 
Lower respiratory 
tract infections. 
Died of norovirus 
GI infection. 
Feeding issues y (temp n/g tube) y y (temp n/g tube) y (temp n/g tube) y (n/g tube) 
Developmental 
Delayf Severe Severe Severe Severe Gross motor delay 
Eyes Blepharophimosis, small eyes 
Blepharophimosis, 
small eyes 
Blepharophimosis, 
small eyes 
Blepharophimosis, 
small eyes, cataract 
Blepharophimosis, 
microphthalmia 
low set ears, 
microtia y y y y y 
Other facial 
features 
Broad forehead, 
late closing 
fontanelle, flat 
nasal bridge 
Scaphocephaly, 
small teeth 
Frontal bossing, 
broad forehead, 
small mandible. 
Prominent lips. 
Prominent lips 
Frontal bossing, 
sparse hair, 
depressed nasal tip, 
smooth philtrum. 
Absent 
subcutaneous fat y y y y y 
Skeletal 
Tapering fingers. 
Small hands and 
feet, 11 pairs of ribs.  
Craniosynostosis. 
Small hands and 
feet, tapering 
fingers. 
Tapering fingers. 
Small hands and 
feet. 
Tapering fingers. 
Small hands and 
feet. Late closing 
fontanelle. 
Tapering fingers. 
Small hands and 
feet. Late closing 
fontanelle. Hip 
dysplasia. 
Haematology 
Lymphopenia. 
Thrombocytopenia 
and anemiad 
Episode 
thrombocytosis. 
Lymphopenia. 
Recurrent 
thrombocytopenia 
and episode 
anemia. 
Lymphopenia. 
Thrombocytopenia 
and anemiad 
Lymphopenia. 
Episode 
thrombocytopenia. 
Immunology IgM, IgA, IgG undetectable Low IgG  Low IgA  
Low IgG. B cell 
aplasia 
Low IgM, IgA, IgG, 
IgE. 
B cell aplasia 
Cardiac PDA, PFO PFO Mild hypertrophic myocardium  
ASD. Pulmonary 
hypertension  
Respiratory 
Chronic wheeze 
and cough, 
progressive airway 
disease, died ARDS 
Mild respiratory 
problems. CXR: 
increased perihilar 
density 
Chronic lung 
disease. CXR: 
infiltrates/ 
consolidation. 
ARDS. 
Chronic respiratory 
insufficiency. 
Oxygen dependent. 
CXR: infiltrates 
Episode of severe 
pneumonitis. 
Diffuse 
parenchymal lung 
disease 
Hepatic Elevated AlkP - 
Elevated LFTs. 
Macronodular 
cirrhosis.  
Elevated LFTs 
Hepatic Fibrosis 
Elevated AlkP. 
Nodular 
hyperplasia. Portal 
hypertension 
Endocrine - n/a Hypothyroid.  GH deficient. Hypothyroid 
Hypothyroid. 
Pancreatic 
insufficiency 
other - - Cryptorchidism Cryptorchidism 
Thymic atrophy. 
Accessory spleen. 
Small kidneys. 
Eczema, severe 
napkin dermatitis. 
Low level mosaic, 
ring chromosomee 
Table 2. Phenotype and clinical features of PRIM1 subjects. 
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mo, months; yrs, years; n/a, not available; GI, gastro-intestinal; Coag. neg Staph, coagulase 
negative Staphyloccous; RSV, respiratory syncytial virus, n/g, nasogastric; Ig, 
immunoglobulin; PDA, patent ductus arteriosus; PFO, patent foramen ovale; ASD, atrial 
septal defect; ARDS, acute respiratory distress syndrome; CXR, chest x-ray; LFTs, liver 
function tests; AlkP, alkaline phosphatase. aLikely older affected male sib, IUGR, description 
similar. bLimited family history available. cExtreme microcephaly/short stature, defined as 
occipital-frontal head circumference (OFC) and height respectively ≤ -4sd from age/sex-
adjusted population mean. dAnemia precipitated by infection. eRing chromosome 20 in 3/30 
cells blood only; not detected skin or buccal. fMotor greater than intellectual delay – latter 
assessed as moderate in P1-4. gblood culture. 

 
 
 
Figure 1. Individuals with Biallelic PRIM1 Variants have Primordial Dwarfism. 
(A) Family pedigrees with segregation of PRIM1 variants as indicated. Square, male; 
circle female; filled symbols, individuals with primordial dwarfism. 
(B) Schematic of PRIM1 transcript and protein. Vertical black lines, exons; location of 
variants indicated by red lines. Primase domain (NCBI CDD cd04860), green; 
nucleotide binding residues, yellow. 
(C) Growth parameters of individuals with PRIM1 deficiency. Z scores (standard 
deviations from population mean for age and sex). Dashed lines, 95% confidence 
interval for general population. Circles, individual subject data points; red bars, mean 
values. 
(D) MRI neuroimaging of P3 demonstrates microcephaly with simplified gyri. Axial T2; 
Sagittal T1. Comparison with age matched healthy controls. Scale bar, 5 cm. 
(E) Photographs of individuals P2-P5. P2, 8 months, P3, 7 months; P4, newborn; P5, 7 
months; . Written consent obtained from families for photography. 
 
  

 
 
 
Figure 2. The c.638+36C>G Variant Creates a Cryptic Splice Donor Site, 
Resulting in Markedly Reduced Cellular PRIM1 Protein Levels. 
(A) The c.638+36C>G variant alters PRIM1 splicing by creating a cryptic splice donor 
site in intron 6. RT-PCR of PRIM1 transcripts from lymphoblastoid cells from P2 and 
primary fibroblasts from P3. Arrows in schematic indicate the position of primers. 
Grey boxes, exons. Red box, retained sequence resulting from mis-splicing. 
(B) Schematic depicting the effect of the c.638+36C>G variant on splicing of intron 6 of 
PRIM1. The reference and alternate sequences of intron 6 shown with positions of 
reference and cryptic splice donor sites marked by dotted lines. SpliceAI scores for 
the donor sites in brackets. 31 nucleotides of included as a result of the c.638+36C>G 
variant are shown on a red background. A sequence logo created with 100,000 
randomly selected human U2 splice donor sites from Ensembl (v83) (Cunningham et 
al. 2015) using WebLogo (Crooks et al. 2004) illustrates how the c.638+36C>G 
substitution creates a strong splice consensus sequence by providing a G at the +5 
position. 
(C) Representative Sanger sequencing traces of splice products relating respectively to 
the lower band from panel A (‘ref splicing’) and the alternatively spliced upper band 
(‘alt splicing’). 
(D) PRIM1 protein levels are markedly reduced in cells from individuals P2 and P3, 
homozygous for the c.638+36C>G variant. Immunoblots of total cell extracts from 
lymphoblastoid cells (P2) and primary fibroblasts (P3). α-tubulin, loading control. C, 
lymphoblastoid, C1, fibroblast cell lines from control subjects. Quantification of 
PRIM1 protein levels for P2 and P3 cells relative to C and C1 controls respectively 
(normalized to α-tubulin loading control) stated beneath each blot. 
 
 
  

 
 
 
Figure 3. The c.103+1G>T and C301R variants reduce PRIM1 protein levels 
(A) Cysteine 301, substituted to arginine in P5, lies in a buried hydrophobic region. DNA 
primase dimer crystal structure (PDB: 4BPU) with residues shaded according to 
solvent accessibility. 
(B) Schematic of the FACS-based dual reporter stability assay. Expression vector 
expresses an mRNA encoding PRIM1-GFP-P2A-FLAG-SR-P2A-RFP. Intervening 
P2A “self-cleaving” peptide sequences produce PRIM1-EGFP, FLAG-SR and RFP 
polypeptides in equimolar amounts. PRIM1-GFP (wildtype and mutants) and RFP 
levels are assayed in individual cells by flow cytometry. PRIM1-GFP and FLAG-SR 
levels can be independently assessed by immunoblotting (See Supplemental Figure 
S3D). 
(C) GFP-RFP scatter plot for wild type, C301R and V35insDGV dual reporter constructs. 
n= WT, 27,027; C301R, 44,863; V35insDGV 46,441 cells respectively. rfu, relative 
fluorescence units. 
(D) Kernel density estimation plot of GFP:RFP ratios from (C). 
(E) Schematic depicting the consequence of the c.103+1G>T variant on splicing. 
Reference and alternate sequences of intron 1 are shown with positions of the 
reference and cryptic splice donor sites marked by dotted lines. SpliceAI scores for 
splice donor sites in brackets. Red box, 9 nucleotides of intron 6 included as a result 
of activation of the cryptic splice donor variant. 
(F) Schematic assaying the effect of the c.103+1G>T variant. Minigene assay. DNA 
spanning exon1 (Ex1) and exon 2 (Ex2) of PRIM1 was cloned into the minigene. 
Arrows, position of PCR primers. Dotted line, splicing from cryptic splice donor. 
(G) Representative cDNA Sanger sequence traces from wild-type (WT) and c.103+1G>T 
variant minigene constructs. The three amino acid (DGV) insertion from the 
c.103+1G>T variant marked in red. 
 
  

 
 
 
Figure 4. Reduced Cell Proliferation and Impaired DNA Replication in PRIM1 
Deficient Primary Fibroblasts. 
(A) Cell doubling time plotted for 3 independent expts on P3 and two unrelated control 
C1 and C2 primary fibroblast cell lines. Bars, mean. Error bars, SD. 
(B) Schematic of CldU/IdU double pulse experiment used to determine S-phase time. 
Cells were labelled with CldU at t = 0 followed by IdU after 1.5 hours. Cells leaving S-
phase (Lcells) are labeled with CldU only, while cells remaining in S-phase (Scells) are 
labeled with both CldU and IdU. Ts, S-phase length, the product of interval between 
pulses (Ti) and the proportion of Scells to Lcells (Martynoga et al. 2005). 
(C) S-phase time is substantially increased in P3 fibroblasts compared to controls. 
Mean±SEM, N=3 expts. 
(D) Schematic of rescue experiment. P3 fibroblast transfected with either empty vector 
(EV), wild-type (WT) or C301R-GFP-PRIM1 as indicated and after 24 h S-phase time 
determined as in (B) for GFP+ve cells. 
(E) Complementation with WT GFP-PRIM1 rescues slow S-phase progression in P3 
fibroblasts. S-phase length plotted for n=3 expts. Mean±SEM. 
(F) DNA content and BrdU flow cytometry scatter plots, representative of 4 independent 
experiments on control (C1, C2) and P3 primary fibroblast cell lines. 
(G) BrdU incorporation is reduced in PRIM1 deficient cells during S-phase. 
Quantification of BrdU mean fluorescence intensity (MFI) from control and patient-
derived fibroblasts according to S-phase gate in (F); a. u., arbitrary units.  
(H) γ-H2AX is increased in S-phase P3 fibroblasts. Mean γ-H2AX intensity calculated for 
EdU-positive nuclei from C1, C2 and P3 cells. n=3 experiments. Data points coloured 
by experiment; filled circles, mean values for each replicate; bars, median and 
interquartile range (all values); values normalised for each experiment relative to C1 
mean value. P-values, repeat-measures ANOVA with Tukey multiple comparison test. 
(I) Representative immunofluorescence images of S-phase nuclei quantified in (H). 
Scale bar, 5 µm. Statistics in A, C, E, and G, one-way ANOVA with Tukey multiple 
comparison test. 
 
  

 
 
 
Figure 5. PRIM1 Deficiency Causes Fork Asymmetry and Increased Inter Origin 
Distances, Consistent with Replication Fork Stalling and Decreased Replication 
Initiation. 
(A) Schematic depicting DNA combing experiments. Sequential 20 minute CldU and IdU 
pulses were performed on cultured primary fibroblasts, which were then harvested, 
with DNA combing performed to characterise DNA replication at the single molecule 
level. 
(B) DNA fork speed, Kbp/min, in primary fibroblasts from two unrelated control 
individuals (C1, C2), a PRIM1-deficient individual (P3), and a POLE-deficient 
individual. Grey and blue dots represent measurements from (n=2) respective 
independent experiments (B-D). 
(C) PRIM1 deficient cells exhibit fork asymmetry, similar to POLE deficient cells. Left (L) 
vs. right (R) fork ratio scatter plots. r, Pearson correlation coefficient. Right, 
representative images of bi-directional forks. Scale bar, 20 µm. 
(D) Inter origin distance (IOD) in control, PRIM1-, and POLE-deficient primary 
fibroblasts; boxplots graphed according to Tukey method (B,D). P-values, Kruskal-
Wallis test. Right, representative images of IODs. Scale bar, 20 µm. 
 
